Table 1 2D Structures of the designed 1, 2, 4-oxadiazole derivatives from the lead

34a

(E)-4-(5-(2-(5-bromothiophen-2-yl) vinyl)-1,2,4-oxadiazol-3-yl)phenol

34b

(E)-3-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)benzene-1,2-diol

34c

(E)-2-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)benzene-1,3-diol

34d

(E)-(3-(5-(2-(5 bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine

34e

(E)-(3-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine

34f

(E)-(2-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol

34g

(E)-(4-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol

34h

(E)-(3-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol

34i

(E)-(2-(5-(2-(5-bromothiophen-2-yl)vinyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol

34j

(E)-5-(2-(5-bromothiophen-2-yl)vinyl)-3-(2-hydrosulfonylphenyl)-1,2,4-oxadiazole